The Impact of Structured Exercise on Brain Health in HIV Positive Individuals

February 10, 2017 updated by: Nancy Mayo, McGill University

Exercise programs that combine resistance exercise with aerobic training yield optimal health benefits for people with HIV. The global aim of this study is to contribute evidence for the impact potential of a comprehensive exercise program on brain health in people with HIV.

This study is part of a larger project based upon a cohort multiple randomized controlled design. Within a fully characterized cohort which is followed over time, people meeting the specific criteria for an exercise intervention will be identified. The sample will be randomly selected to receive the intervention; the remaining eligible persons will serve as controls. The intervention group will receive a 45 minute structured exercise program 3 times a week consisting of aerobic exercise and resistance training for a total of 12 weeks.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Exercise is an inexpensive intervention with widespread benefits to vascular and musculoskeletal health and few harms. Showing an additional benefit to brain health and cognition in particular is likely to encourage adoption and help elucidate mechanisms underpinning brain health in HIV.

The primary objective of the study is to estimate, in comparison to individuals not offered the exercise intervention, the extent to which a comprehensive exercise program impacts on indicators of brain health, where these indicators are the primary outcome of cognitive ability (B-CAM) and the related brain health outcomes of depression, anxiety, fatigue, motivation, and speed of motor performance.

A secondary objective is to estimate the extent to which changes in brain health are mediated through exercise induced changes in brain network function as measured by EEG and/or by exercise induced changes in muscle power, aerobic capacity, physical function, and body composition.

Study Type

Interventional

Enrollment (Anticipated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Quebec
      • Montreal, Quebec, Canada, H3A 1A1
        • Recruiting
        • Division of Clinical Epidemiology
        • Contact:
        • Contact:
        • Principal Investigator:
          • Nancy Mayo, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

35 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

The exercise intervention will target individuals recruited from two Montreal clinics who identified at cohort entry they were interested in being approached for different trials if they eligible.

Inclusion Criteria:

  • men and women aged ≥ 35 years, HIV+ for at least 1 year, able to communicate adequately in either French or English, and able to give written informed consent.

Also, participants must identify that they are mostly sedentary by reporting that they perform moderate level physical activity of 30 minutes duration less than twice a week or have limitations in performing vigorous activities, walking a kilometer, or climbing stairs. Individuals answering yes to any of the Physical Activities Readiness Questionnaire (PAR-Q) (Thomas et al., 1992) items except taking medication (Item 6) will require clearance from their physician to be included.

Exclusion Criteria:

  • people with dementia (MOCA < 18) or treating physician's concern about capacity to consent, life expectancy of < 3 years or other personal factors limiting the ability to participate in follow-up, non-HIV-related neurological disorder likely to affect cognition, known active CNS opportunistic infection or hepatitis C requiring interferon (IFN) treatment during the follow-up period, psychiatric disorder on the psychotic axis, current substance use disorder or severe substance use disorder within the past 12 months.

Also excluded will be people with a contraindication for exercise from cardiovascular or musculoskeletal co-morbidity as gathered from the medical history and from the PAR-Q (Thomas et al., 1992).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Exercise group
The 45 minute exercise program will be performed 3 times a week and will consist of aerobic exercise and resistance training for 12 weeks.
Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
No Intervention: Control
No treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Cognitive Ability
Time Frame: 0 and 39 weeks
The primary outcome is cognitive ability as measured by B-CAM. This is part of the measurement platform for all and the value taken at the regular assessment prior to the exercise intervention will serve as the baseline value and the subsequent evaluation 9 months following will serve as the follow-up value. The strategy ensures that the intervention cohort does not have additional measurements of cognitive ability than the control cohort. The items on the B-CAM fit the Rasch Model and as such have linearized units on a logit scale.
0 and 39 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in depression
Time Frame: 0 and 39 weeks
Measured by Hospital Anxiety and Depression Scale (HADS)
0 and 39 weeks
Change in depression
Time Frame: 0 and 39 weeks
Measured by RAND -36 Mental Health Inventory (MHI)
0 and 39 weeks
Change in stress levels
Time Frame: 0 and 39 weeks
Measured by Trier Inventory for Chronic Stress (TICS)
0 and 39 weeks
Change in anxiety
Time Frame: 0 and 39 weeks
Measured by Hospital Anxiety and Depression Scale (HADS)
0 and 39 weeks
Change in fatigue
Time Frame: 0 and 39 weeks
Measured by RAND-36 Vitality
0 and 39 weeks
Change in motivation
Time Frame: 0 and 39 weeks
Measured by Motivation Ladder
0 and 39 weeks
Change in global quality of life (QOL)
Time Frame: 0 and 39 weeks
Measured by Person Generated Index (PGI)
0 and 39 weeks
Change in health related quality of life (HRQoL)
Time Frame: 0 and 39 weeks
Measured by RAND-36
0 and 39 weeks
Change in health related quality of life (HRQoL)
Time Frame: 0 and 39 weeks
Measured by WHOQOL-HIV
0 and 39 weeks
Change in measures of brain network function
Time Frame: 0 and 12 weeks
The measures of brain network function are derived from event related potential (ERPs) which are electric potentials produced by the brain in response to auditory or visual stimulation, respectively. These brain responses are easily recorded noninvasively with scalp electrodes (EEG). ERPs allow insights into the neural mechanisms underlying specific cognitive processes. The potentials of interest here include the N1, N2, P2 and P3 ERPs.
0 and 12 weeks
Change in skeletal muscle mass
Time Frame: 0 and 12 weeks
A total body Dual energy X-ray absorptiometry (DEXA) scan will be done to compute skeletal muscle mass (whole body, spine and thigh) (Lee & Gallagher, 2009).
0 and 12 weeks
Change in muscle quality
Time Frame: 0 and 12 weeks
Peripheral quantitative computed tomography (pQCT) will be used to measure the muscle quality in lower extremity (MacIntyre & Lorbergs, 2012).
0 and 12 weeks
Change in exercise capacity
Time Frame: 0 and 12 weeks
Measured by step test
0 and 12 weeks
Change in functional walking capacity
Time Frame: 0 and 12 weeks
Measured by Six Minute Walk Test (6MWT)
0 and 12 weeks
Change in quadriceps power
Time Frame: 0 and 12 weeks
Measured using leg press and jump test
0 and 12 weeks
Change in core strength
Time Frame: 0 and 12 weeks
Measured using curl ups/push ups
0 and 12 weeks
Change in grip strength
Time Frame: 0 and 12 weeks
Measured using hand dynamometer
0 and 12 weeks
Change in gait speed
Time Frame: 0 and 12 weeks
Comfortable gait speed: GAITRite; Fast gait speed: GAITRite; Dual task gait speed: GAITRite and naming the fruits
0 and 12 weeks
Change in exercise enjoyment
Time Frame: 0 and 12 weeks
Exercise enjoyment will be measured by Physical Activity Enjoyment Scale (PACES) (Mullen et al., 2011).
0 and 12 weeks
Change in physical activity
Time Frame: 0, 6 and 12 weeks
The data from the accelerometer will be used to estimate the extent to which the structured exercise program carries over into everyday life. Participants will be asked to wear an ActivPal accelerometer for 5-7 days prior to the start of the intervention, at 6 weeks, and after 12 weeks, to objectively measure habitual physical activity.
0, 6 and 12 weeks
Change in semantic fluency
Time Frame: 0 and 12 weeks

Following question will be asked:

Name as many animals as you can in 1 minute (in sitting).

0 and 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nancy E Mayo, PhD, McGill University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2015

Primary Completion (Anticipated)

January 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

January 20, 2017

First Submitted That Met QC Criteria

February 10, 2017

First Posted (Actual)

February 15, 2017

Study Record Updates

Last Update Posted (Actual)

February 15, 2017

Last Update Submitted That Met QC Criteria

February 10, 2017

Last Verified

February 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV

Clinical Trials on Exercise group

Subscribe